Alexandra Collin de L’hortet

Alexandra (Alex) Collin de l’Hortet is Epic Bio’s head of therapeutics. Dr. Collin de l’Hortet leads the efforts to transform the powerful technology platform of epigenomic engineering into a new class of gene therapy medicines.

Dr. Collin de l’Hortet has over ten years of experience managing biomedical research. Prior to joining Epic Bio, she worked at Krystal Biotech, where she provided scientific and strategic leadership to the product development team, and managed several gene therapy programs from discovery through to Phase III. Prior to Krystal, Dr. Collin de l’Hortet served as a research assistant professor at the University of Pittsburgh.

Dr. Collin de l’Hortet earned her M.Sc. in genetics and her Ph.D. in molecular biology and therapeutics from the University of Paris.